ALS Patients Exhibit Altered Levels of Total and Active MMP-9 and Several Other Biomarkers in Serum and CSF Compared to Healthy Controls and Other Neurologic Diseases
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26188900 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Robert Bowser und 4 weiteren Autor:innen. Beteiligte Einrichtung: nVector, Inc, 124 W. Thomas Road STE 200, Phoenix, AZ 85013, USA. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Matrix Metalloproteinase 9, Biomarkers, Nervous System Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Defense (DOD) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA).
Abstract (Originalsprache)
Matrix metalloproteinases 2 and 9 (MMP-2, MMP-9) have been implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS). However, their protein levels and correlation with other biomarkers are not well understood. We measured total and active MMP-2/-9 and additional biomarkers (creatinine, neurofilament light, cystatin C, and alkaline phosphatase) in the serum of people with ALS (ALS, n = 30) and compared their levels with age-matched healthy controls (HC, n = 20) and other neurological diseases (diabetic nephropathy, Alzheimer’s disease, Parkinson’s disease; n = 8 each). We also measured MMP-2/-9 in a set of CSF samples from ALS (n = 30) and age-matched other neurological diseases (OND, n = 14). Lastly, we measured the competitive binding behavior of a dual MMP-2/MMP-9 inhibitor, AQU-118, against active MMP-9 in situ within the serum of ALS. We found significantly elevated levels of both total MMP-9 protein (two studies, 7.5 and 9.5-fold; both p < 0.0001) and active MMP-9 (2.5-fold; p < 0.0001) in ALS serum compared to HC. Serum NfL was significantly elevated (6-fold, p < 0.0001) and serum creatinine was significantly decreased (40%, p < 0.0001) in ALS compared to HC. There were significantly decreased levels of MMP-2 (two studies, 26 and 33%; p < 0.001 and p = 0.0001, respectively) in the serum of ALS as compared to HC. ALS also had significantly higher active MMP-9 in serum than patients with Alzheimer’s disease and higher than Parkinson’s disease or diabetic nephropathy. We confirmed that active MMP-9 in ALS is fully available for proteolytic activity in both serum and CSF and can be inhibited using an MMP-2/-9 inhibitor. Active MMP-9 is systemically elevated in ALS and therefore a therapeutic target for ALS drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- nVector, Inc, 124 W. Thomas Road STE 200, Phoenix, AZ 85013, USA.
- Advansta, Inc., 2140 Bering Drive, San Jose, CA 95131, USA.
- Boston University School of Medicine, 72 E. Concord St., Boston, MA 02118, USA.
- Aquilus Pharmaceuticals, Inc., 225 Mystic Valley Parkway, Winchester, MA 01890, USA.
ORCID-Profile: Irving Sucholeiki
Förderung
- Department of Defense (DOD) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA)
Zitieren
APA
Bowser, R., An, J., Schwartz, K., Sucholeiki, R. L., & Sucholeiki, I. (2025). ALS Patients Exhibit Altered Levels of Total and Active MMP-9 and Several Other Biomarkers in Serum and CSF Compared to Healthy Controls and Other Neurologic Diseases. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26188900
Vancouver
Bowser R, An J, Schwartz K, Sucholeiki RL, Sucholeiki I. ALS Patients Exhibit Altered Levels of Total and Active MMP-9 and Several Other Biomarkers in Serum and CSF Compared to Healthy Controls and Other Neurologic Diseases. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26188900
BibTeX
@article{Bowser2025,
author = {Bowser, Robert and An, Jiyan and Schwartz, Kimberly and Sucholeiki, Robert L and Sucholeiki, Irving},
title = {ALS Patients Exhibit Altered Levels of Total and Active MMP-9 and Several Other Biomarkers in Serum and CSF Compared to Healthy Controls and Other Neurologic Diseases},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26188900}
}
EUVIMED